Overview

Osteoclast Inhibition and Bone Formation

Status:
Completed

Trial end date:
2016-10-25

Target enrollment:

Participant gender:

Summary

This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?

Phase:

Early Phase 1

Details

Lead Sponsor:

Mayo Clinic

Treatments:

Denosumab